The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Gang, Gallant, Joseph, Zheng, Jian, Massey, Christopher, Shi, Ke, Tai, Wanbo, Odle, Abby, Vickers, Molly, Shang, Jian, Wan, Yushun, Du, Lanying, Aihara, Hideki, Perlman, Stanley, LeBeau, Aaron, Li, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Microbiology and Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354634/
https://www.ncbi.nlm.nih.gov/pubmed/34338634
http://dx.doi.org/10.7554/eLife.64815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354634/
https://www.ncbi.nlm.nih.gov/pubmed/34338634
http://dx.doi.org/10.7554/eLife.64815

Ejemplares similares